vs
Stoke Therapeutics, Inc.（STOK）与Travere Therapeutics, Inc.（TVTX）财务数据对比。点击上方公司名可切换其他公司
Stoke Therapeutics, Inc.的季度营收约是Travere Therapeutics, Inc.的1.2倍（$158.6M vs $129.7M），Stoke Therapeutics, Inc.同比增速更快（3661.1% vs 73.4%）
Stoke Therapeutics是一家临床阶段生物技术企业，专注开发靶向RNA的创新疗法，用于治疗严重罕见遗传病。其领先候选药物针对德拉韦综合征等罕见癫痫及其他单基因神经系统疾病，满足全球患者未被满足的医疗需求。
Travere Therapeutics是一家全球生物制药企业，专注于为罹患罕见、严重且危及生命疾病的患者开发和商业化创新疗法，核心覆盖罕见肾病、肝病及代谢疾病领域，业务覆盖北美、欧洲等主要市场。
STOK vs TVTX — 直观对比
营收规模更大
STOK
是对方的1.2倍
$129.7M
营收增速更快
STOK
高出3587.7%
73.4%
损益表 — Q1 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $158.6M | $129.7M |
| 净利润 | $112.9M | — |
| 毛利率 | — | 98.0% |
| 营业利润率 | 70.2% | -25.0% |
| 净利率 | 71.2% | — |
| 营收同比 | 3661.1% | 73.4% |
| 净利润同比 | 528.0% | — |
| 每股收益（稀释后） | $1.90 | $0.04 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收STOKTVTX
| Q4 25 | — | $129.7M | ||
| Q3 25 | — | $164.9M | ||
| Q2 25 | — | $114.4M | ||
| Q1 25 | $158.6M | $81.7M | ||
| Q4 24 | $22.6M | $74.8M | ||
| Q3 24 | — | $62.9M | ||
| Q2 24 | — | $54.1M | ||
| Q1 24 | — | $41.4M |
净利润STOKTVTX
| Q4 25 | — | — | ||
| Q3 25 | — | $25.7M | ||
| Q2 25 | — | $-12.8M | ||
| Q1 25 | $112.9M | $-41.2M | ||
| Q4 24 | $-10.5M | — | ||
| Q3 24 | — | $-54.8M | ||
| Q2 24 | — | $-70.4M | ||
| Q1 24 | — | $-136.1M |
毛利率STOKTVTX
| Q4 25 | — | 98.0% | ||
| Q3 25 | — | 99.0% | ||
| Q2 25 | — | 98.7% | ||
| Q1 25 | — | 94.3% | ||
| Q4 24 | — | 96.6% | ||
| Q3 24 | — | 97.4% | ||
| Q2 24 | — | 96.2% | ||
| Q1 24 | — | 96.4% |
营业利润率STOKTVTX
| Q4 25 | — | -25.0% | ||
| Q3 25 | — | 15.1% | ||
| Q2 25 | — | -11.1% | ||
| Q1 25 | 70.2% | -52.2% | ||
| Q4 24 | -60.4% | -81.2% | ||
| Q3 24 | — | -89.3% | ||
| Q2 24 | — | -125.1% | ||
| Q1 24 | — | -336.5% |
净利率STOKTVTX
| Q4 25 | — | — | ||
| Q3 25 | — | 15.6% | ||
| Q2 25 | — | -11.1% | ||
| Q1 25 | 71.2% | -50.4% | ||
| Q4 24 | -46.4% | — | ||
| Q3 24 | — | -87.1% | ||
| Q2 24 | — | -130.1% | ||
| Q1 24 | — | -328.9% |
每股收益（稀释后）STOKTVTX
| Q4 25 | — | $0.04 | ||
| Q3 25 | — | $0.28 | ||
| Q2 25 | — | $-0.14 | ||
| Q1 25 | $1.90 | $-0.47 | ||
| Q4 24 | $-0.15 | $-0.71 | ||
| Q3 24 | — | $-0.70 | ||
| Q2 24 | — | $-0.91 | ||
| Q1 24 | — | $-1.76 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $274.8M | $93.0M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $350.1M | $114.8M |
| 总资产 | $406.9M | $605.2M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资STOKTVTX
| Q4 25 | — | $93.0M | ||
| Q3 25 | — | $110.9M | ||
| Q2 25 | — | $75.2M | ||
| Q1 25 | $274.8M | $61.9M | ||
| Q4 24 | $128.0M | $58.5M | ||
| Q3 24 | — | $36.4M | ||
| Q2 24 | — | $32.3M | ||
| Q1 24 | — | $43.3M |
股东权益STOKTVTX
| Q4 25 | — | $114.8M | ||
| Q3 25 | — | $73.6M | ||
| Q2 25 | — | $32.7M | ||
| Q1 25 | $350.1M | $32.8M | ||
| Q4 24 | $229.0M | $59.1M | ||
| Q3 24 | — | $-30.5M | ||
| Q2 24 | — | $15.1M | ||
| Q1 24 | — | $74.1M |
总资产STOKTVTX
| Q4 25 | — | $605.2M | ||
| Q3 25 | — | $538.6M | ||
| Q2 25 | — | $555.3M | ||
| Q1 25 | $406.9M | $548.8M | ||
| Q4 24 | $271.6M | $594.1M | ||
| Q3 24 | — | $504.4M | ||
| Q2 24 | — | $551.1M | ||
| Q1 24 | — | $663.5M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $131.8M | $60.7M |
| 自由现金流经营现金流 - 资本支出 | $131.7M | — |
| 自由现金流率自由现金流/营收 | 83.0% | — |
| 资本支出强度资本支出/营收 | 0.1% | — |
| 现金转化率经营现金流/净利润 | 1.17× | — |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势，按日历期对齐
经营现金流STOKTVTX
| Q4 25 | — | $60.7M | ||
| Q3 25 | — | $14.3M | ||
| Q2 25 | — | $5.0M | ||
| Q1 25 | $131.8M | $-42.2M | ||
| Q4 24 | $-23.2M | $-35.7M | ||
| Q3 24 | — | $-42.5M | ||
| Q2 24 | — | $-40.2M | ||
| Q1 24 | — | $-119.0M |
自由现金流STOKTVTX
| Q4 25 | — | — | ||
| Q3 25 | — | $14.2M | ||
| Q2 25 | — | — | ||
| Q1 25 | $131.7M | — | ||
| Q4 24 | $-23.2M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | $-40.3M | ||
| Q1 24 | — | — |
自由现金流率STOKTVTX
| Q4 25 | — | — | ||
| Q3 25 | — | 8.6% | ||
| Q2 25 | — | — | ||
| Q1 25 | 83.0% | — | ||
| Q4 24 | -102.7% | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | -74.5% | ||
| Q1 24 | — | — |
资本支出强度STOKTVTX
| Q4 25 | — | — | ||
| Q3 25 | — | 0.1% | ||
| Q2 25 | — | — | ||
| Q1 25 | 0.1% | — | ||
| Q4 24 | 0.2% | — | ||
| Q3 24 | — | 0.0% | ||
| Q2 24 | — | 0.2% | ||
| Q1 24 | — | 0.0% |
现金转化率STOKTVTX
| Q4 25 | — | — | ||
| Q3 25 | — | 0.56× | ||
| Q2 25 | — | — | ||
| Q1 25 | 1.17× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
STOK
暂无分部数据
TVTX
| FILSPARI | $103.3M | 80% |
| Tiopronin Products | $23.3M | 18% |
| License | $3.1M | 2% |
